Regeneron Maintains Its Momentum During Pandemic
Executive Summary
The company reported strong 33% revenue growth in Q1, despite softer Eylea sales from postponed treatments, progressed in oncology, and is moving an antibody cocktail for COVID-19 into clinical testing.
You may also be interested in...
BIO 2020 Notebook: McMurry-Heath On Restoring Hope, Greenwood On Defeating Climate Skeptics
News and views from day one of BIO Digital: Industry leaders discuss speeding up drug development amid COVID-19; new CEO Michelle McMurry-Heath wants to restore hope in populations that feel left behind; and former CEO Jim Greenwood aims to defeat politicians who deny climate change.
BIO 2020 Notebook: McMurry-Heath On Restoring Hope, Greenwood On Defeating Climate Skeptics
News and views from day one of BIO Digital: Industry leaders discuss speeding up drug development amid COVID-19; new CEO Michelle McMurry-Heath wants to restore hope in populations that feel left behind; and former CEO Jim Greenwood aims to defeat politicians who deny climate change.
‘Friendly Breakup’: Sanofi And Regeneron Agree Equity Revamp
Sanofi to sell most of its Regeneron stake, with much of it being re-purchased by Regeneron, but both stressed the move would not hurt their long established and very profitable drug-development collaboration.